- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05838560
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a pilot study that will enroll up to 40 participants and will examine the following:
- test the safety and feasibility of dasatinib+quercetin in two mental illnesses associated with accelerated aging: schizophrenia and treatment-resistant depression
- examine changes in SASP (senescence-associated secretory phenotype) with dasatinib+quercetin treatment
- examine acute and long-term changes in neuropsychological functioning, functional status, and brain markers of aging, as well as in clinical symptoms of the illnesses (treatment-resistant depression and schizophrenia).
This study will also combine the treatment of dasatinib plus quercetin and lifestyle-based risk factor management - which will involve the research team during the medication intervention portion to provide lifestyle education focusing on strength, balance, and nutrition. The research team will maintain close contact with participants to offer encouragement, address questions and help navigate barriers to engaging in the activities.
Before study enrollment, participants will be screened using questionnaires and a phone screen prior to being consented.
The participant will be involved for about 1 year and self-administer 8 total doses of the medications - two consecutive days of dasatinib 100mg orally plus quercetin 1250mg orally on weeks 1 (ie., 2 days on, 5 days off), 2, 3, and 4.
The participant will undergo an MRI scan at baseline and approximately week 10 of the study.
Blood draws will occur at baseline, week 1, 2, 3, 4, 10, and at the endpoint. 10 ml of blood will be taken each time for 700 ml over 1 year.
Participants will have several questionnaires and assessments to complete at baseline, week 10, and the study's endpoint.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Marissa Rhea
- Phone Number: 314-362-3797
- Email: marissa@wustl.edu
Study Contact Backup
- Name: Julia Schweiger
- Phone Number: 314-362-3153
- Email: schweigj@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Eric Lenze, MD
-
Contact:
- Julie Schweiger
- Phone Number: 314-362-3153
- Email: schweigj@psychiatry.wustl.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder.
- Age 50+ (60+ for depression).
- Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging).
- No history of dementia by patient report.
- Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression.
Exclusion Criteria:
- Contraindications for dasatinib or quercetin
- Active SI such that participant could not be safely managed in an outpatient clinical trial.
- Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin).
- All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dasatinib + quercetin
open label dasatinib plus quercetin combined as a drug therapy
|
dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who successfully completed and safely tolerated the intervention
Time Frame: 10 weeks
|
Test the safety and feasibility of dasatinib plus quercetin
|
10 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Eric Lenze, MD, Washington University School of Medicine, Department of Psychiatry
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mood Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Depressive Disorder
- Depression
- Schizophrenia
- Psychotic Disorders
- Mental Disorders
- Depressive Disorder, Treatment-Resistant
- Aging, Premature
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Protein Kinase Inhibitors
- Antioxidants
- Dasatinib
- Quercetin
Other Study ID Numbers
- 202302203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Dasatinib + quercetin
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHead and Neck Squamous Cell CarcinomasChina
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
The University of Texas Health Science Center at...Mayo ClinicCompletedAlzheimer DiseaseUnited States
-
TruDiagnosticActive, not recruiting
-
Wake Forest University Health SciencesThe University of Texas Health Science Center at San AntonioRecruitingMild Cognitive Impairment | Alzheimer Disease, Early OnsetUnited States, Spain
-
Mayo ClinicRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingNAFLD | Liver Fibrosis | NASH With FibrosisNetherlands
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingFrailty | Childhood CancerUnited States
-
Mayo ClinicEnrolling by invitation
-
Odense University HospitalNovo Nordisk A/S; Odense Patient Data Explorative NetworkRecruiting